OpenNashPodcasts

Making Sense (J.P. Morgan)

The Growing Appetite for Obesity Drugs

1 Dec 2023 · 24m · Chris Schott, Richard Vosser, Elif Korkmaz · 24 quoted facts

▶ Play episodeOriginal source ↗

In brief

J.P. Morgan analysts argue that GLP-1 obesity drugs could become the largest drug category ever, with a global market above $100 billion. They say the drugs are unusual because patients actively want them. The SELECT trial suggests treating weight itself reduces heart attacks, strokes and diabetes. That could shift healthcare from treating each condition separately to treating obesity as the common cause.

The central tension is huge demand against limited access. Supply, insurance coverage and price all limit who can get the drugs today. The analysts expect these limits to ease as factories expand, prices fall and employers cover the drugs. They see Novo Nordisk and Eli Lilly staying ahead, and see pills as the long-term answer to capacity. Open questions are how long people stay on treatment and what happens when they stop.

Key insights

  1. Obesity drugs now show proven heart benefits

    The SELECT study found Wegovy cut heart attacks, strokes and cardiovascular deaths by about 20%. The analysts say this reframes weight loss as a way to prevent disease, not just a cosmetic goal.

  2. Demand has far outrun the supply of drugs

    Novo spent five or six years building the market with a drug that produced only about 5% weight loss. Newer drugs passed 10%, and demand overwhelmed projections. Chris Schott says new capacity takes about three years to build.

  3. List prices overstate what payers actually pay

    Chris Schott says list prices are not what employers pay, and expects net prices of a few thousand dollars a year. Richard Vosser expects prices to fall around 10% a year, as diabetes prices have.

  4. Novo Nordisk and Lilly are expected to stay ahead

    The analysts say both firms have decades of experience, big budgets and a head start. Their next drugs target 25% to 30% weight loss, versus about 15% for catching-up rivals such as Amgen and Pfizer.

  5. Stopping treatment tends to bring weight back

    Chris Schott says patients usually regain most of their weight quickly after stopping. That supports the view that these will be long-term medicines, though the analysts expect mixed use and are unsure about maintenance doses.

Questions

What are GLP-1 drugs and how do they make people lose weight?

GLP-1s began as diabetes drugs. Richard Vosser says they reduce appetite in two ways: by increasing the feeling of fullness in the stomach and by strengthening the brain's signal that you have eaten enough.

Why are people so excited about the SELECT study?

It showed that Wegovy, a Novo Nordisk drug, cut the risk of heart attacks, strokes and cardiovascular death by about 20%. The analysts say this suggests treating excess weight directly prevents many downstream health problems.

Will insurers and employers pay for obesity drugs?

Chris Schott says it is 'a matter of when, not if', and expects most major employers to cover them within five to seven years. Richard Vosser says Novo's coverage is already around 50 million, though patients still face hurdles.

Why is it hard to get these drugs right now?

Demand has far exceeded what Novo and others expected, and building factories and injection pens takes about three years. Novo is limiting new patients to protect supply for people already on the drug.

Are these drugs safe, and do you have to stay on them forever?

Richard Vosser says there are no safety issues beyond tolerability, such as feeling unwell in the first month or two, and about 20% of patients can't tolerate them. Chris Schott says most weight comes back if people stop, so many will likely stay on them long term.

Facts

Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.

J.P. Morgan analysts expect the global market for GLP-1 drugs to exceed $100 billion over time.

“From the perspective of the pharma companies, we see the market for the GLP-1 category exceeding $100 billion over time globally.”

0:00:04 · Elif Korkmaz · Market size

Chris Schott says about 40% of the U.S. population is obese.

“think about the US, you've got 40 % of the population is obese”

0:02:27 · Chris Schott · Obesity prevalence

Chris Schott says the leading makers of the newer GLP-1 drugs are Novo Nordisk and Eli Lilly.

“It's really two players right now. So it's Novo Nordisk and it's Eli Lilly.”

0:03:37 · Chris Schott · Competition · 2023

Chris Schott says newer GLP-1 drugs are producing weight loss of 20, 30 or even 50 pounds in patients' first year.

“We're now starting to see patients losing 20, 30, 50 pounds of weight over the first year they're on a medication.”

0:04:05 · Chris Schott · Efficacy

Novo Nordisk released results of its SELECT cardiovascular outcomes study in August 2023, which coincided with a split in healthcare stock performance.

“especially around August when we had the select study from NOAA Nordisk looking at the cardiovascular outcomes”

0:04:27 · Elif Korkmaz · SELECT study · 2023

Medical device companies underperformed in 2023 amid fears about the impact of GLP-1 drugs.

“While companies on the medical device side of things, they really underperformed over these GLP-1 fears.”

0:05:00 · Elif Korkmaz · Stock performance · 2023

The SELECT study showed Wegovy reduced the risk of heart attacks, strokes and cardiovascular death by about 20%.

“not only helped people to lose weight, but also reduced their risk of suffering from heart attacks, strokes, cardiovascular deaths by 20%”

0:05:00 · Elif Korkmaz · SELECT study · 2023

Chris Schott notes the 20% cardiovascular benefit in SELECT came with only 10 to 15% body weight loss, and expects larger benefits from stronger drugs.

“if we have a 20 % benefit for these patients, only losing 10 or 15 % of their body weight”

0:06:47 · Chris Schott · SELECT study

Chris Schott says Novo Nordisk and Eli Lilly have upcoming drugs producing roughly 25% weight loss.

“Novo has drugs coming that's 25%. Lilly's in the same range.”

0:07:21 · Chris Schott · Pipeline

J.P. Morgan's Chris Schott has estimated the U.S. obesity drug opportunity at approaching $50 billion by 2030.

“you previously said that you estimate obesity opportunity in the U.S. approaching 50 billion by 2030”

0:08:01 · Elif Korkmaz · Market size · 2030

Richard Vosser says Novo Nordisk's coverage for its obesity drug is now around 50 million, covering most commercially insured U.S. patients.

“So their coverage is now somewhere in the region of 50 million. So they've got the bulk patients in the US.”

0:09:58 · Richard Vosser · Insurance coverage · 2023

Richard Vosser says diabetes drug prices have been falling by about 10% a year and expects obesity drug prices to follow.

“the idea that diabetes prices have been coming down by 10 % a year”

0:10:29 · Richard Vosser · Pricing

Chris Schott assumes obesity drugs will cost only a few thousand dollars a year once access is broadly available.

“We're assuming these things will only cost a few $1,000 a year when you look out to when access is broadly available.”

0:10:50 · Chris Schott · Pricing

Novo Nordisk spent five or six years building the obesity market with an earlier drug that produced only about 5% weight loss, according to Richard Vosser.

“And they hadn't got very far because the drug that they were using only made people lose 5 % of the body weight.”

0:12:26 · Richard Vosser · Obesity history

Chris Schott says it takes about three years from deciding to add manufacturing capacity to having it available.

“the lead time here is about three years from when you decide you need capacity to when you can get it”

0:13:34 · Chris Schott · Supply

Chris Schott says Eli Lilly recently added a facility that doubles its capacity for these drugs.

“Lilly just added a facility that doubles their capacity.”

0:13:34 · Chris Schott · Supply · 2023

Chris Schott expects Eli Lilly's oral obesity drug, now in phase three trials, to report data in 2025 and launch in 2026.

“they're in phase three. It's the last phase of development. We'll see data in 2025. We'll launch the drugs in 2026.”

0:14:31 · Chris Schott · Oral drugs · 2026

Chris Schott says Amgen and Pfizer are developing rival obesity drugs but that Novo Nordisk and Eli Lilly have decades of head start.

“there's companies like Amgen and Pfizer that are working. But Novo and Lilly have spent decades working on this class of medication.”

0:14:56 · Chris Schott · Competition

Richard Vosser says the next generation of Novo Nordisk and Eli Lilly drugs should deliver 25 to 30% weight loss, versus about 15% from catch-up rivals.

“Novo and Lily's next generation products are going to be delivering 25, 30 % weight loss in that sort of category.”

0:15:25 · Richard Vosser · Pipeline

Richard Vosser says GLP-1 drugs have been on the market for 10 to 15 years with no safety issues beyond tolerability.

“we've got lots and lots of years of safety data. We've talked about this for 10 years or so, 15 years these products have been on the market.”

0:17:37 · Richard Vosser · Safety

Chris Schott says patients who stop GLP-1 medications tend to regain most of their weight fairly quickly.

“if you stop taking these medications, the patients tend to regain a majority of their weight fairly quickly”

0:18:34 · Chris Schott · Weight regain

Richard Vosser says about 20% of patients do not tolerate these drugs, while 75% in the SELECT trial stayed on the drug for three to four years.

“About 20 % of patients don't tolerate these drugs. But the vast majority we've seen in the data from the SLECT trial, 75 % of patients stayed on the drug for about three to four years.”

0:20:44 · Richard Vosser · Adherence

Richard Vosser says there are around 32 million diabetics in the U.S. and a similar number in Europe.

“You've got around 32 million diabetics US, same in Europe or so.”

0:21:09 · Richard Vosser · Diabetes market

Chris Schott says some Eli Lilly data show about half of diabetic patients on its drug bring their blood sugar back to normal.

“some of the Lilly data, like half the patients who go on these medications get their blood sugar back down to normal”

0:22:41 · Chris Schott · Diabetes efficacy

Chapters

  1. 0:00:27Why GLP-1s have captured public attention

    Sets up the episode and why these drugs are drawing unusual interest from ordinary people, not just investors.

    “Everyone wants to talk about these.”
  2. 0:01:22How the drugs work and who makes them

    Explains the appetite mechanism and introduces Novo Nordisk and Eli Lilly as the two leading players.

    “they basically modify your appetite in two ways”
  3. 0:06:31SELECT trial and the shift to treating weight

    Shows why cardiovascular results matter: obesity is treated as a cause of other diseases, not a separate lifestyle issue.

    “you should just go in and treat the weight itself”
  4. 0:08:41Insurance coverage and real-world pricing

    Explains why the analysts expect broad employer coverage and why list prices overstate what payers pay.

    “this is a matter of when, not if”
  5. 0:12:26Supply shortages and capacity expansion

    Describes why demand outstripped supply and how long it takes to build manufacturing capacity.

    “demand has far outstripped the projections that Novo or anybody else had”
  6. 0:14:31Oral pills and the competitive landscape

    Covers when pills could arrive and why the analysts see the market as a Novo-Lilly duopoly.

    “We'll see data in 2025. We'll launch the drugs in 2026.”
  7. 0:18:34Tolerability, regain and long-term use

    Discusses side effects, safety history, weight regain after stopping and how many patients stay on treatment.

    “almost as fast as it goes off, it comes back on”
  8. 0:21:09Market size across diabetes and obesity

    Compares the diabetes and obesity opportunities and why obesity may end up larger.

    “we see them as equally sized markets”

Transcript

0:00:04
Elif Korkmaz

There has been a lot of excitement around GLP-1s as a groundbreaking new class of drugs for the treatment of diabetes and obesity. From the perspective of the pharma companies, we see the market for the GLP-1 category exceeding $100 billion over time globally. Today, we are here to discuss what these drugs are, how they could lead to a big paradigm shift in healthcare in tackling the obesity epidemic, and some of the big controversies.

0:00:27
Chris Schott

Outside of work, usually no one wants to ask me questions about like what new exciting drugs are coming to the market. That's not the case with GLP-1s. Everyone wants to talk about these. And I think that's something unique I'm seeing in this space. I've covered the drug industry for 20 years. I've never seen this kind of broader societal level discussion around a new class of medications like this.

0:00:45
Elif Korkmaz

Hello and welcome to Research Recap on J.P. Morgan's Making Sense podcast channel. My name is Elif Korkmaz and I cover healthcare specialist sales at J.P. Morgan in New York. Today, I'm joined by my colleagues, Chris Schott, Senior U.S. Pharma Analyst, and Richard Vosser, Senior European Pharma Analyst. Welcome both.

0:01:04
Chris Schott

Thanks for having us.

0:01:05
Elif Korkmaz

So, Richard, let's start with you. So, there has been a ton of excitement around GLP-1s, and it has been one of the core investment themes in healthcare this year. Can you help us put this all in perspective? Maybe let's go back to basics and help us understand what all this excitement is about.

0:01:22
Richard Vosser

Hey, Elise. Hey, everyone. So GLP-1s have been around for quite a while. They started off as diabetes drugs, and they've been pretty good at treating diabetes. But as a side effect of the treatment of diabetes, they are pretty good at making people lose weight. And how do they do that? They basically modify your appetite in two ways. So they act on your stomach. So the idea of feeling full. So, you know, if you've ever eaten a lot of steak, then you'll know that you feel pretty full after a large meal.

0:01:56

And that's the feeling of fullness that they accentuate. So that makes you eat less. And they also act on your brain. So the feeling of satiety, the feeling of that you've eaten and that you should stop, they make that greater as well. And that side effect, if you like, of their mechanism of action has now been put to use as an indication in itself for the treatment of obesity. So that's what it's all about. There's been this new class of drugs that can actually, for the first time ever, deliver meaningful weight loss.

0:02:27
Chris Schott

And maybe, Richard, just building on that, this whole idea of obesity, I mean, it's obviously such an epidemic. I mean, think about the US, you've got 40 % of the population is obese. So this is, in our view, one of the kind of bigger unmet needs in the market. And I think what's unique about this class of drugs is you typically don't see patients wanting to take medication. So if I think about kind of other big classes of drugs, cholesterol, blood pressure, it's usually a doctor saying something's wrong with you.

0:02:53

Take this pill. You won't look any different. You won't feel any different. And it's a little bit of a challenge to get some of the patients engaged. That's not the case here. I'm a drug analyst. Outside of work, usually no one wants to ask me questions about like what new exciting drugs are coming to the market. That's not the case with GLP-1s. Everyone wants to talk about these. And I think that's something unique I'm seeing in this space.

0:03:12

I've covered the drug industry for 20 years. I've never seen this kind of broader societal level discussion around a new class of medications like this. And I think there's the potential to capture both sides of this where we have a huge market opportunity. And also we have patients on their side who actually are really excited about getting on these medications.

0:03:29
Elif Korkmaz

That's really helpful, Chris. And just for the audience, if you can help us better understand the landscape, what options that are available out there and some of the key players.

0:03:37
Chris Schott

Yeah, sure. So Richard and I talk a lot about this. It's really two players right now. So it's Novo Nordisk and it's Eli Lilly. And I think what's been different about what's happening currently is we've been talking about this class of drugs for 15 years. And as Richard mentioned, they're great diabetes medications, but that wasn't the most exciting thing for the broader world. The newer medications, though, so we think about drugs like Ozempic in diabetes, Wagovi in obesity, Monjaro, which is an Eli Lilly drug coming to market.

0:04:05

These are drugs that have profoundly better efficacy than we've seen previously. So if you took an older class of GLP-1s, you might lose a few pounds. Sure, that's great. We're now starting to see patients losing 20, 30, 50 pounds of weight over the first year they're on a medication. That's a very different dynamic. And I think that's capturing the public's attention to a much greater extent than we've seen previously.

0:04:27
Elif Korkmaz

Absolutely. I mean, these drugs really rose to prominence in the mainstream media with celebrities being on it. But I think from the investment perspective, we saw a pretty historic moment this summer with GLP-1 trade, right? There was a massive bifurcation of performance in healthcare stocks, especially around August when we had the select study from NOAA Nordisk looking at the cardiovascular outcomes. And we saw a big divergence in performance, you know, stocks like Elioli, NOAA Nordisk and companies involved in the whole GLP-1 supply chain and manufacturing outperforming significantly.

0:05:00

While companies on the medical device side of things, they really underperformed over these GLP-1 fears. And to me, what was really interesting is when we looked at select results, it showed that Vigovi not only helped people to lose weight, but also reduced their risk of suffering from heart attacks, strokes, cardiovascular deaths by 20%. This is a huge, profound impact that could have further implications for the healthcare space broadly, right? And the treatment paradigm. Do you guys want to take a minute to discuss about select and how do we view the landscape there?

0:05:32
Richard Vosser

Yeah, maybe I'll take that one first. I think that's the whole point, isn't it? So Chris has talked about patients want to take the drugs, right? They want to lose weight. So there's quite a lot of pull from patients. But what the SELECT study does is it tells you why you should be losing weight. And then that has implications downstream, which I'm sure Chris will talk about. But the why you want to lose weight is because the weight is causing a lot of downstream issues with health.

0:06:02

You know, there is a direct cause now from the obesity of cardiovascular risk, so the risk of having a heart attack. And as you said, the 20 % reduction on that was shown in select. But it's not just the risk of a heart attack. It is the risk of progression to diabetes, which is not only hugely costly for the healthcare systems, but it also leads to worse health outcomes cardiovascularly, but also for your kidneys. All sorts of things go wrong.

0:06:31

And we're really just at the tip of the iceberg there. And that's what Select brings. It brings this idea that instead of waiting to treat the downstream effects, the comorbidities of excess weight, you should just go in and treat the weight itself.

0:06:47
Chris Schott

Yeah, and just building on that, it seems like a paradigm shift. rather than kind of treating all these different conditions as separate, somewhat unrelated conditions, there's a common denominator, which is these conditions tend to affect patients who are obese to a much, much greater extent than the broader population. So I think what's interesting as we think about this data, Wagovi is a great drug. There's even better drugs coming. You know, if we have a 20 % benefit for these patients, only losing 10 or 15 % of their body weight, I think Richard and I are both pretty excited when we think about ZEP bound for Lilly, where that weight loss is 20%.

0:07:21

Novo has drugs coming that's 25%. Lilly's in the same range. So we think that these data sets will only get more impressive over time. And then you think about just what this means from a payer perspective. We'll talk about that a little bit as can we afford medications like this? But if you can take a drug that reduces your risk of a heart attack, reduces your risk of death, reduces your risk of sleep apnea, stroke, effectively prevents diabetes in these patients, It's hitting on so many elements of cost in the healthcare system that it kind of comes back to this issue of why we're thinking of this as the largest drug category we've ever seen.

0:07:57

We just never have seen a medication that will touch on all those different issues with one drug.

0:08:01
Elif Korkmaz

Absolutely, Chris. I mean, like you highlighted, all these outcome studies really put obesity in perspective as a chronic epidemic condition as opposed to a lifestyle change. And that's going to be key for coverage perspective. And kind of touched on this, but this is one of the biggest controversies for the class of drugs. You've done significant work on obesity markets. And you previously said that you estimate obesity opportunity in the U.S. approaching 50 billion by 2030.

0:08:29

That's a very big number. Can you help us better understand your assumptions there getting to that number? Also, from an access and insurance perspective, where are we now? And will insurers broadly cover GLP-1s for obesity?

0:08:41
Chris Schott

Yeah, and this is something we talk a lot about with investors is basically everyone wants these drugs, but will everyone be able to get these drugs? And I'm sure anyone who's tried to get these medications, there's a lot of hoops to jump through right now. Our thought is this is a matter of when, not if. We think most major employers, the idea of their employees' health is increasingly kind of front and center with all these wellness programs.

0:09:03

This, again, comes back to it touches on so many elements of health that we could see a situation where employers want to see more data. They want to see this play out. But I think as we dig into that data, it's just hard to dispute the findings that we're seeing here. So we'll talk about this a little bit when it comes to capacity. There may be some dynamics here where the companies are keeping the price a bit higher because they can't meet demand.

0:09:27

Maybe we'll see some employers initially target patients who are of more severe risk than other patients for the initial use of these medications. But as you start to ramp capacity, as price comes down, we're thinking looking out five or seven years, it's pretty much just going to be standard that major employers cover these medications. Richard, I know with NOAA, they've kind of led the charge on building this initial access and educating employers about obesity. What are you seeing in terms of where coverage is today and how that could improve over time?

0:09:57

Yeah, their coverage builds every time you speak

0:09:58
Richard Vosser

to them. So their coverage is now somewhere in the region of 50 million. So they've got the bulk patients in the US. So they've got the bulk of the available market outside of Medicare, which is the over 65s. They've got the bulk of the commercial, which is pre 65. Now, as you alluded to, there's a few hoops to jump through and those hoops will come down, but the broad coverage is there. The broad employer opt-ins are also there coming through over time.

0:10:29

Now, when we think about price, I think what we should probably talk about is the idea that diabetes prices have been coming down by 10 % a year. And I think that's what we're going to see here. A couple of 10 % a year forever downwards. That's what we're going to see as the supply builds, as the access comes through. And I think what we're talking about,

0:10:50
Chris Schott

we get these questions often, we see it at the press a lot, that the list price of these drugs is very high. That's really not what employers are paying. And that number is only going to come down over time. So we're talking about pricing. We're assuming these things will only cost a few $1,000 a year when you look out to when access is broadly available. And again, relative to the benefit you're getting, I don't think it's a hard decision for a lot of payers to look at that.

0:11:13

So I kind of like to address that controversy as we do hear that a lot from folks that there's a lot of press around, can the system afford these? Are they too expensive? And I think a lot of times it's looking at that list price versus what an actual kind of net price will end up being when these companies end up negotiating discounts.

0:11:27
Elif Korkmaz

Absolutely. And, you know, speaking of access, one of the other key issues that we're currently facing is supply challenges, right? A lot of people are eligible for these drugs, but that doesn't necessarily mean that they can access it. Demand really has really outstripped supply recently. Richard, maybe we turn to you on, can you please talk about where we are currently? It's available at Vagovie in the U.S. and maybe if you can talk us through what NOAA is doing to overcome these supply challenges?

0:11:55
Richard Vosser

Yeah, completely. I mean, the restrictions are there and they're restricting the starter doses so that they are available for patients as they start. They can progress on to higher doses to generate higher weight loss so that patients can go through to be able to achieve their maximal dose. So in order to make sure that patient experience is there, They're restricting the number of patients that they will allow on the drug to start with. Now, that comes back to the problem.

0:12:26

The problem is that demand has far outstripped the projections that Novo or anybody else had for the drugs in the first place. Novo had been building this market with obesity, and Chris touched on it earlier, for about five or six years. And they hadn't got very far because the drug that they were using only made people lose 5 % of the body weight. And then the current round of drugs, this tipping point of over 10 % led to overwhelming demand.

0:12:57

And so it takes time once you have much greater demand to ramp up the supply chain, just the physical building of sites to do this, getting the pens that these are delivered in, etc. That takes a lot of time. And so, Novo, we're working through this. What we'd expect is supply to continuously ramp up over the next few years. And we're going to be talking about supply effectively, I think, from Novo, ultimately doubling, doubling, and doubling again.

0:13:30

And I think that's pretty similar when it comes to Lilly as well.

0:13:34
Chris Schott

Yeah, usually they can make as much as you want of the drug, but no one wants to take it. This is a different situation. So from that perspective, the lead time here is about three years from when you decide you need capacity to when you can get it. And to Richard's point, I mean, Lilly just added a facility that doubles their capacity. They had another facility of similar size basically every year for the next four years.

0:13:55

That may not even meet the demand that's out there. And I think as we then talk about where this eventually goes, I know both companies here are also working on oral medications. probably ultimately going to be required to really fully satisfy the market is you need to turn these things into pills. You can't make enough auto-injector pens to keep up with demand ultimately. And 2026 and beyond, I think that's a reality that those will become a much more prevalent kind of delivery mechanism versus having to inject yourself.

0:14:21
Elif Korkmaz

Chris, for orals, how close do you think we are to having a viable oral on the market? And can you also talk about some of the other players that are trying to enter the space?

0:14:31
Chris Schott

Sure. And I know Richard and I debate this a lot of the various companies working on it, but from a Lilly perspective, they're in phase three. It's the last phase of development. We'll see data in 2025. We'll launch the drugs in 2026. I know Novo has some oral agents there working and we're probably in similar timeframes. They're taking it different ways, but I kind of thinking about three years from now, these are probably more mainstream drugs than what we see currently.

0:14:56

And then we think about the broader market. It is one that we think of this as kind of a duopoly, that there's companies like Amgen and Pfizer that are working. But Novo and Lilly have spent decades working on this class of medication. They spend more money than anybody else out there. They have such a head start. It's just hard for us to envision someone really catching up. So we think of this as these two companies really leading innovation for the foreseeable future.

0:15:24

Richard, I don't know if anything you'd add.

0:15:25
Richard Vosser

Yeah, I'd just build on that. And from that innovation that you're saying, it's the idea that Novo and Lily's next generation products are going to be delivering 25, 30 % weight loss in that sort of category. Whereas the people who are trying to catch up are going to be delivering sort of 15 % weight loss as far as we can see. So they're not going to have enough efficacy or enough weight loss, I should say, to really compete with Novo and Lily.

0:15:51

They keep their competitive advantage, if you like. And then on the orals, the orals are going to have to be safe, right? To your point on working on this for a very long time, these drugs took some refinement to be able to make them tolerable. And not all drugs reached the market back in the day. And I think the orals are going to go through this. And I think, again, Novo and Lilly have a head start.

0:16:16

Lilly's in phase three. Novo have the data already for their oral. They just need to be able to make enough. A recurring theme.

0:16:23
Chris Schott

Yes, exactly. It's an interesting point you bring up, Richard, about the whole issue of safety and tolerability, because I get that question a lot. The main issue with these drugs is really one more about tolerability than safety. So, as Richard mentioned before, this changes the way your body processes how you feel when you eat. So, there's some patients who go on these medications and think these are some wonder drug where you take a shot once a week, you eat what you want, suddenly you miraculously lose weight, and they don't quite work that way.

0:16:52

So I do think there's going to be an education process that helps patients better manage these things, that you do have to eat a little bit less, you maybe have to eat slightly different food. And to be fair, that's not going to be for everybody. Not everyone's going to want to change their diet. But we do think there's enough motivation in the broader market that for many patients who go on these drugs, you're going to get that tolerability issue where you don't feel great for the first month or two.

0:17:14

But once you get through that, these are some of the drugs with the highest compliance rates we see in the market because people, the side effects go away and they generally feel better, they look better and they're happy to be on the medication. So I think that's, again, one of these other issues we think about, it'll take time, but ultimately we kind of think of these almost becoming chronic medications as compared to something you maybe take for some short window of time and then go off therapy.

0:17:37
Richard Vosser

Just to broaden that, Chris, in terms of on the safety, we've got lots and lots of years of safety data. We've talked about this for 10 years or so, 15 years these products have been on the market. And they've accumulated a lot of use in patients. And there really are no safety issues other than the tolerability issues that you've just spoken about, Chris. So that's, I think, very reassuring the data there from a safety perspective.

0:18:03
Elif Korkmaz

I mean, speaking of length of use and duration on treatment, right, if these are going to be chronic lifelong medications, where are we currently on the average duration on the drug? Also, you know, what happens to patients once they stop taking the drug? Do they put the weight back on? And if you're thinking about maintenance therapy, do you also see a role for some of the oral options that might lead to less weight loss, but that could be more tolerable and could be used more chronically?

0:18:34
Chris Schott

Sure, I'll start there and turn over to Richard. But from our perspective, I think every physician is going to tell the patient this is a chronically used medication. and we probably all don't listen to what our doctors say. So realistically, not everyone's going to do that. What we do see with the data, however, is if you stop taking these medications, the patients tend to regain a majority of their weight fairly quickly. So almost as fast as it goes off, it comes back on.

0:19:01

So there is an incentive for the patient that it's not like you lose 30 pounds, you stop taking the drug, you hold that weight, you'll start regaining weight. So as we think about the market, as we see more outcomes data suggesting you get all of these health benefits, I think it'll be an easier message to the patient. Yeah, you're losing weight, but also these drugs are keeping you alive longer, so you probably don't want to stop taking them.

0:19:22

That's not where we are today. So we're kind of thinking of this as some people take it chronically, some people take it intermittently. It's not one size fits all. And to your point in the longer term, I don't think we know how that's going to play out. There very well may be a maintenance dose that's an oral, maybe it's less frequently dosed, that just helps you sustain weight when you no longer need to lose weight. I think we're probably just in the early part of the curve here.

0:19:44

We're just trying to figure out how big is the demand and kind of get that initial weight loss in before we're worrying so much about how do you sustain it from there.

0:19:51
Richard Vosser

I'd just add that when you look from the doctor's side as well, they're going to be encouraging the patients to stay. So, you know, when they prescribe you a blood pressure lowering agent, they don't just say, here's your blood pressure agent, here's your blood pressure, it's come down, and then say, stop taking it because we've got it down. They say, take it forever because they know that low blood pressure forever gives you a benefit on your health.

0:20:19

And it's the same here. Coming back to the select trial has shown you should take these drugs for a long period of time to get health benefits. So there's going to be motivation from both sides. It's going to be physician motivation because they know the health benefits and there's going to be patient motivation that Chris has spoken about that they feel better, the mirror is going to be the measure there. And as Chris says, it's not going to be for everybody.

0:20:44

About 20 % of patients don't tolerate these drugs. But the vast majority we've seen in the data from the SLECT trial, 75 % of patients stayed on the drug for about three to four years. So Chris is right. There's going to be mixed use, but people will generally stay. Definitely. Richard, taking

0:21:03
Elif Korkmaz

a step back, how are you thinking about the market size and the split between diabetes and obesity?

0:21:09
Richard Vosser

And how do you get to your numbers? Yeah, so Chris and I debate this all the time. So numbers generally tend upwards. But from a diabetes and obesity point of view, we see them as equally sized markets. You've got around 32 million diabetics US, same in Europe or so. You're further advanced in terms of the use of GLP-1s in diabetes. They're about 15 % usage rate today. Everybody who's a diabetic should be on these drugs.

0:21:39

Weight loss improves diabetes, blood glucose control, these are the best. So we're going to head towards that and that's going to drive substantial use. And then obesity, it's going to take a good length of time to penetrate this market. There's hundreds of millions of obese people in the US and Europe each. But of course, it's probably going to be a lower use rate to start with. So we see the similar size at the moment. But what do you think, Chris?

0:22:07

Do you think obesity ends up being bigger? I'm probably in the

0:22:11
Chris Schott

camp that it probably does end up being bigger. And I think that's an area where we think that probably is more upside than just reinforce what you're saying. I know this conversation has been about obesity, there's a lot of type 2 diabetics. And these medicines are profoundly better medications than anything we've ever seen. So I think as drug analysts, we're probably really excited about that setting in particular, because this has been such a hard to treat disease, where there's lots of medications you take, and all they do is try to keep your disease from progressing.

0:22:41

They don't actually make you better. And we're seeing these drugs for the first time, some of the Lilly data, like half the patients who go on these medications get their blood sugar back down to normal. So they're no longer diabetic. We've never, ever seen that in data sets before. And the obesity side, I think you just get to this point where it's becoming this kind of cultural phenomena. And if there is a medication you can take and lose a lot of weight, and there may be ways of doing that that are pills, maybe they're weekly injections, maybe they're monthly injections, you can kind of choose what you want.

0:23:12

I'm assuming over time, you're going to see a lot of patients wanting to get access to that. So ultimately, when you think about that market opportunity, we have 40 % of the patient population is obese. So it's really hard to fight those numbers, even at a very low price. It ends up with a huge revenue opportunity in that

0:23:30
Elif Korkmaz

it affects most of the population. Well, Chris, Richard, thank you. This has been a great conversation. I think there's a lot of excitement, rightfully so, around the topic. It seems like over the next few years, there are a lot of new developments coming into space and the category is going to be profoundly impactful for healthcare with far-reaching consequences just beyond pharmaceuticals. I want to thank you again for joining me today. For more information, you can go to jpmorgan.com forward slash research.

0:23:56

And thank you again.

0:23:58
Chris Schott

Thanks, everyone, for listening. Thanks for listening. Thanks for listening to Research Recap. If you've enjoyed this conversation, we hope you'll review, rate and subscribe to JPMorgan's Making Sense to stay on top of the latest industry news and trends. Available on Apple Podcasts, Spotify, Google Podcasts and YouTube. This communication is provided for information purposes only. Please read J.P. Morgan Research Reports related to its contents for more information, including important disclosures. Copyright 2023, J.P. Morgan Chase & Co., all rights reserved.